Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase ...

DNP-002 is under development for the treatment of solid tumor. It is administered through intravenous route. The therapeutic candidate binds to the epitope present on carcinoembryonic antigen-related ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Incendia Therapeutics has enrolled the first subject in a Phase Ic clinical trial of PRTH-101, a novel DDR1 inhibitor aimed ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Asunercept is under clinical development by Apogenix and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) ...

Broadcom has an excellent growth runway, substantial sales and profitability growth potential, and is relatively cheap now.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Kineta will be trading under the symbol “KANT” on OTC PinkKineta will continue to pursue strategic alternatives as previously announcedTuHURA ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...